Research Analysts Offer Predictions for SPRO Q3 Earnings

Spero Therapeutics, Inc. (NASDAQ:SPRO) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Spero Therapeutics in a report released on Monday, September 14th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 price objective on the stock. HC Wainwright also issued estimates for Spero Therapeutics’ Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.88) EPS.

Other equities analysts have also recently issued research reports about the stock. Compass Point upgraded shares of Spero Therapeutics to a “neutral” rating in a research note on Monday. Weiss Ratings raised shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

Spero Therapeutics Stock Performance

NASDAQ SPRO opened at $1.14 on Tuesday. Spero Therapeutics has a one year low of $1.08 and a one year high of $3.08. The stock has a 50-day moving average of $1.34 and a 200 day moving average of $2.11. The company has a market capitalization of $66.39 million, a price-to-earnings ratio of 10.36 and a beta of 1.49.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%.

Institutional Trading of Spero Therapeutics

Hedge funds have recently bought and sold shares of the company. Alphabet Inc. bought a new position in Spero Therapeutics in the second quarter valued at about $1,967,000. BlackRock Inc. bought a new stake in shares of Spero Therapeutics during the 2nd quarter valued at about $1,314,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Spero Therapeutics during the 2nd quarter valued at about $36,000. Global Retirement Partners LLC purchased a new stake in shares of Spero Therapeutics during the 2nd quarter valued at about $55,000. Finally, GSA Capital Partners LLP bought a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $632,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.